Jones Financial Companies
HRTX icon

Jones Financial Companies’s Heron Therapeutics HRTX Stock Holding History

Jones Financial Companies’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.19K Sell
12,062
-18,000
-60% -$14.4K ﹤0.01% 4076
2026
Q1 		$23.5K Buy
30,062
+2,107
+8% +$2.44K ﹤0.01% 3234
2025
Q4 		$36.3K Buy
27,955
+3,867
+16% +$4.78K ﹤0.01% 2673
2025
Q3 		$29.1K Buy
24,088
+23,661
+5,541% +$37.5K ﹤0.01% 2605
2025
Q2 		$914 Buy
+427
New +$872 ﹤0.01% 3676
2025
Q1 		– Sell
-476
Closed -$728 – 3780
2024
Q4 		$728 Buy
+476
New +$772 ﹤0.01% 3189

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Jones Financial Companies's HRTX Position: Q2 2026 in Review

Jones Financial Companies reduced its Heron Therapeutics (HRTX) stake by 60% in Q2 2026, selling an estimated $14.4K and leaving 12,062 shares worth $5.19K. The position accounts for ﹤0.01% of the portfolio, ranked #4076.

Jones Financial Companies first reported a position in HRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $36.3K in Q4 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Jones Financial Companies held 12,062 shares of Heron Therapeutics worth $5.19K as of Q2 2026.
  • Jones Financial Companies sold 18,000 Heron Therapeutics shares in Q2 2026, an estimated $14.4K.
  • Heron Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4076 holding.
  • Jones Financial Companies first reported a position in Heron Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Jones Financial Companies's Heron Therapeutics position peaked at $36.3K in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.